However, malignant relapse was a major reason for treatment failure in these patients with high-risk hematologic malignancies and was possibly caused by cyclophosphamide-mediated deletion of tumor-specific CD8+ T cells (54, 70). Here, CD8A is linked to hematologic disorder.